R. Legare

发表

Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features

D. Sgroi, S. Schnitt, R. Gelman, 2010, Breast Cancer Research.

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Peter Marynen, Rafeul Alam, Jan Cools, 2003, The New England journal of medicine.

TargetedT-cell Therapy in Stage IVBreastCancer : A Phase I Clinical Trial

A. Thakur, D. Dizon, Qin Liu, 2015 .

Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial

A. Thakur, D. Dizon, Qin Liu, 2015, Clinical Cancer Research.

Choosing high-risk screening vs. surgery and the effect of treatment modality on anxiety and breast-specific sensuality in BRCA mutation carriers.

C. Raker, K. Robison, A. Stuckey, 2019, Gland surgery.

Addressing clinical trials: can the multidisciplinary Tumor Board improve participation? A study from an academic women's cancer program.

C. Raker, A. Stuckey, D. Dizon, 2010, Gynecologic oncology.

Advances in Medical Management of Early Stage and Advanced Breast Cancer: 2015.

W. Sikov, R. Legare, B. Sakr, 2016, Seminars in radiation oncology.

Clinical Characteristics and Choices Regarding Risk-Reducing Surgery in BRCA Mutation Carriers

A. Stuckey, D. Dizon, R. Legare, 2010, Gynecologic and Obstetric Investigation.

A Stage I-III B Stage IV Stage I-IIA Stage IIA-IIB Stage IIB-III Surgery

W. Sikov, R. Legare, B. Sakr, 2015 .

Outcomes for Women Receiving Bevacizumab for Treatment of Ovarian Cancer Versus Other Solid Tumors at an Academic Oncology Center

K. Robison, A. Stuckey, D. Dizon, 2013 .

For Women Receiving Chemotherapy for Clinically Apparent Early Ovarian Cancer, Is There a Benefit to Surgical Staging?

S. Weitzen, D. Dizon, P. DiSilvestro, 2008, American journal of clinical oncology.

Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study.

J. Gribben, D. Neuberg, D. Gilliland, 1998, Blood.

Prediction of therapy‐related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma

J. Gribben, D. Gilliland, L. Nadler, 1997, American journal of hematology.

Management of hematological malignancies during pregnancy

J. Castillo, A. Mega, R. Legare, 2009, American journal of hematology.

Adjuvant therapy in breast cancer.

R. Legare, R. Strenger, 2002, Obstetrics and gynecology clinics of North America.

Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia

John M. Maris, Katheleen Gardiner, John H. Bushweller, 1999, Nature Genetics.

Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers

S. Gautam, A. Richardson, D. Sgroi, 2010, Breast Cancer Research.

TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).

E. Winer, S. Schnitt, J. Garber, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk factors for breast cancer.

R. Legare, Stephen S Falkenberry, Robert D Legare, 2002, Obstetrics and gynecology clinics of North America.

Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer.

Richard O. Moore, S. Weitzen, A. Rojan, 2006, Gynecologic oncology.

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

D. Fabbro, D. Neuberg, J. Kutok, 2003, Cancer cell.

Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program.

Richard O. Moore, A. Rojan, D. Dizon, 2006, Gynecologic oncology.

Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2.

M. Leppert, D. Gilliland, J. Aster, 1996, Blood.

Chapter 3 – The Genetics of Breast and Gynecologic Cancers

A. Rojan, R. Legare, J. S. Wilbur, 2007 .

Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.

D. Dizon, W. Sikov, R. Legare, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): A BrUOG study.

L. Harris, V. Bossuyt, G. Chung, 2012 .

Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals.

K. Robison, A. Stuckey, R. Legare, 2012, Gynecologic oncology.

Genetics: predisposition and management.

R. Legare, 2011, Clinical obstetrics and gynecology.

Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study

David A. Edmondson, A. Stuckey, M. Lopresti, 2021, Breast Cancer Research and Treatment.

Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital.

D. Dizon, C. Bandera, R. Legare, 2007, Gynecologic oncology.

Recruitment Strategies for a Home-Based Physical Activity Intervention for Breast Cancer Patients

B. Pinto, B. Cady, Carolyn Rabin, 2004, Journal of Clinical Psychology in Medical Settings.

Myelodysplastic syndrome

G. Gilliland, R. Legare, 1995, Current opinion in hematology.

Neoadjuvant therapy for stage II-III breast cancer with weekly nab-paclitaxel, every-three-week carboplatin, and targeted agents: Interim dose delivery and toxicity data.

L. Harris, W. Sikov, R. Legare, 2010 .

Risk factors for breast cancer.

R. Legare, S. Falkenberry, 2002, Obstetrics and gynecology clinics of North America.